- Home
- ASMB vs PLX Comparison
ASMB vs PLX Comparison
Compare ASMB & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- PLX
- Stock Information
- Founded
- ASMB 2005
- PLX 1993
- Country
- ASMB United States
- PLX United States
- Employees
- ASMB N/A
- PLX N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASMB Health Care
- PLX Health Care
- Exchange
- ASMB Nasdaq
- PLX Nasdaq
- Market Cap
- ASMB 141.8M
- PLX 127.4M
- IPO Year
- ASMB 2010
- PLX 1998
- Fundamental
- Price
- ASMB $18.86
- PLX $1.42
- Analyst Decision
- ASMB Strong Buy
- PLX Strong Buy
- Analyst Count
- ASMB 3
- PLX 1
- Target Price
- ASMB $33.00
- PLX $15.00
- AVG Volume (30 Days)
- ASMB 29.0K
- PLX 546.0K
- Earning Date
- ASMB 08-15-2025
- PLX 08-13-2025
- Dividend Yield
- ASMB N/A
- PLX N/A
- EPS Growth
- ASMB N/A
- PLX N/A
- EPS
- ASMB N/A
- PLX 0.05
- Revenue
- ASMB $32,154,000.00
- PLX $59,764,000.00
- Revenue This Year
- ASMB $0.04
- PLX $10.00
- Revenue Next Year
- ASMB N/A
- PLX $83.13
- P/E Ratio
- ASMB N/A
- PLX $29.48
- Revenue Growth
- ASMB 148.33
- PLX 0.18
- 52 Week Low
- ASMB $7.75
- PLX $0.82
- 52 Week High
- ASMB $19.93
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ASMB 55.48
- PLX 43.15
- Support Level
- ASMB $16.90
- PLX $1.41
- Resistance Level
- ASMB $19.43
- PLX $1.53
- Average True Range (ATR)
- ASMB 1.05
- PLX 0.07
- MACD
- ASMB -0.09
- PLX 0.00
- Stochastic Oscillator
- ASMB 75.38
- PLX 4.35
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.